WallStreetZenWallStreetZen

NASDAQ: BDRX
Biodexa Pharmaceuticals PLC Stock Ownership - Who owns Biodexa Pharmaceuticals?

Insider buying vs selling

Have Biodexa Pharmaceuticals PLC insiders been buying or selling?
No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when BDRX insiders and whales buy or sell their stock.

BDRX Shareholders

What type of owners hold Biodexa Pharmaceuticals PLC stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Boothbay Fund Management LLC0.02%44,593$35.72kInstitution
Renaissance Technologies LLC0.00%11,700$9.37kInstitution
Bank Of America Corp0.00%5,236$4.19kInstitution
Gamma Investing LLC0.00%1,036$829.84Institution
Ubs Group Ag0.00%600$480.60Institution
Rhumbline Advisers0.00%498$398.90Institution
Morgan Stanley0.00%16$12.82Institution
Concourse Financial Group Securities Inc0.00%0$0.00Institution

1 of 1

BDRX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
BDRX0.02%0.00%
AMPE0.90%99.10%Net Buying
CYTO1.93%0.00%
SPRC2.62%0.00%
TCBP1.05%98.95%

Biodexa Pharmaceuticals Stock Ownership FAQ

Who owns Biodexa Pharmaceuticals?

Biodexa Pharmaceuticals (NASDAQ: BDRX) is owned by 0.02% institutional shareholders, 0.00% Biodexa Pharmaceuticals insiders, and 99.98% retail investors. Boothbay Fund Management LLC is the largest individual Biodexa Pharmaceuticals shareholder, owning 44,593.00 shares representing 0.02% of the company. Boothbay Fund Management LLC's Biodexa Pharmaceuticals shares are currently valued at $38.31k.

If you're new to stock investing, here's how to buy Biodexa Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.